Duopa

Quick links to important sections

Duopa

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Duopa

Property Description
Active ingredients Levodopa, Carbidopa
Form Enteral Suspension (Intestinal Gel)
Pharmacological Class Dopaminergic Agent, Anti-Parkinson's Agent
Common Use Dopamine replacement therapy
Origin Synthetic, Combination Product

Duopa: Defining the Drug and Its Pharmacological Class

Duopa is a unique prescription medication classified as a Dopaminergic agent and Anti-Parkinson's agent, designed to supply critical neurotransmitter precursors to the brain. This synthetic drug is fundamentally a combination product that forms the basis of Dopamine replacement therapy. The formulation belongs to the category of Anti-Parkinson's agents, which are used to manage conditions related to a deficiency of the chemical messenger Dopamine in the brain. Its primary purpose is to address this underlying chemical deficiency by efficiently delivering the necessary chemical components to the central nervous system, which is essential for supporting motor function.


Composition and Unique Enteral Suspension Form

Duopa contains two active ingredients, Levodopa and Carbidopa, and is formulated as an enteral suspension—a sterile, viscous intestinal gel—designed for continuous delivery. This formulation differentiates itself from conventional oral tablets, as its delivery method via a tube requires a specialized intestinal gel form, which is packaged in a cassette. The composition includes Levodopa, which is the Dopamine precursor, and Carbidopa, which is included to serve as a decarboxylase inhibitor. This protective function is intended to enhance bioavailability to the central nervous system. The role of Carbidopa is to protect the Levodopa from being broken down outside the brain, thereby increasing the amount that reaches the central nervous system where it is needed for conversion into Dopamine.


How Duopa's Continuous Delivery Supports Function

The use of an enteral suspension enables the continuous administration of the medicine, which provides a steady, consistent level of the active ingredients. This unique delivery mechanism is the key differentiating factor, functioning to maintain stable plasma concentrations. Providing this sustained, consistent chemical support is intended to generally help stabilize and manage the physical difficulties associated with the condition by ensuring the brain receives a more continuous supply of the chemical building blocks it requires.

What side effects are possible with Duopa?

Possible Side Effects and Safety Information

The official safety profile of Duopa (levodopa/carbidopa enteral suspension) classifies adverse reactions based on how frequently they are documented in clinical use, focusing primarily on effects related to the central nervous and gastrointestinal systems.

Adverse reactions are formally categorized according to regulatory frequency standards:

  • Very Common (ge 1/10): Reactions that are most frequently observed include Dyskinesia, Nausea, Constipation, Insomnia, Fall, and Parkinsonism aggravated. These effects are often related to the dopaminergic component of the medication.
  • Common (ge 1/100 to <1/10): Commonly documented effects include Diarrhea, Vomiting, Upper abdominal pain, Anxiety, Headache, Dizziness, Hallucinations, Confusional state, and Hypertension.

Serious Adverse Reactions

The regulatory label highlights several clinically significant, though less frequent, safety considerations. These include the documented risk of developing Impulse Control Disorders (ICD), such as pathological gambling, which is associated with dopaminergic therapies. Neuroleptic Malignant Syndrome (NMS) is a serious condition noted as a risk in association with rapid withdrawal or reduction of the drug's dosage. Additionally, Malignant Melanoma is a documented risk noted in the context of long-term dopaminergic exposure.

Safety Considerations

Specific patterns noted in official documents include reactions that may be more likely during the initial treatment or dose adjustment, such as dyskinesia. Administration-agnostic safety restrictions note that use with non-selective monoamine oxidase inhibitors (MAOIs) is associated with the risk of severe hypertension.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of carbidopa and levodopa enteral suspension (Duopa/Duodopa) requires immediate emergency medical attention, as noted in official regulatory documents. Overdose symptoms are primarily motor and cardiac in nature.

Documented Overdose Presentations

System Affected Clinical Manifestations (from regulatory documents)
Neurological/Motor Dystonia (involuntary muscle contractions), Dyskinesia (uncontrolled sudden movements), Blepharospasm (involuntary eyelid spasm—may be an early sign)
Cardiac Cardiac arrhythmias (irregular heart rhythms)
General Symptoms may be associated with the overdose of the levodopa/carbidopa component.

Required Emergency Actions

In the event of a suspected overdose, the following steps are explicitly directed by regulatory labeling:

  • Seek immediate medical help or contact a Poison Control Center.
  • Electrocardiographic (ECG) monitoring should be used to carefully observe the patient for the development of cardiac arrhythmias.
  • If arrhythmias occur, appropriate antiarrhythmic therapy should be administered as necessary.
  • Other potential ingested substances should be considered during the clinical assessment.

The regulatory information also notes that the use of pyridoxine (Vitamin B6) is not expected to reverse the effects of an overdose, and the value of dialysis in the treatment of a Duopa overdose is currently unknown. The severity of an overdose can range from early signs like blepharospasm to life-threatening complications such as sustained cardiac arrhythmias.

Therapeutic Uses of Duopa

What DUOPA Treats: Main Uses and Benefits

The primary therapeutic application of DUOPA is applied in addressing the motor fluctuations often associated with advanced Parkinson's disease. This specialized treatment is commonly used in clinical settings that involve acute or unstable symptom patterns, relevant when supportive symptom management is appropriate. The focus is on conditions characterized by periods of heightened symptoms and those involving episodic or fluctuating manifestations.

DUOPA is considered relevant for easing symptoms that become more disruptive during flare-ups. This includes symptoms associated with acute or episodic changes, such as 'off' periods, troublesome dyskinesia, and symptoms of increased neurological or muscular activity. The continuous, device-assisted delivery helps ease the overall symptom burden. The support provided is relevant for easing discomfort and contributes to improved comfort during periods of heightened symptoms. One patient-oriented benefit is that the treatment may assist with maintaining functional stability during symptomatic periods.

Quick Fact: Relief for Motor Symptoms


Eligibility and Restrictions for Use

The use of Duopa is strictly governed by a patient's medical history and current physiological state, as defined in official regulatory documents.

Populations Allowed and Contraindicated

Classification Eligibility Criteria (Must Be Present or Absent)
Contraindicated (Must NOT Use) Concomitant use of nonselective Monoamine Oxidase (MAO) inhibitors (or within 14 days), known hypersensitivity to any component, narrow-angle glaucoma, or a history of melanoma or undiagnosed suspicious skin lesions.
Recommended (Must Meet) Patients with advanced Parkinson's disease experiencing motor fluctuations who have shown a clear and positive responsiveness to levodopa therapy.
Not Established Safety and effectiveness have not been established in pediatric patients (under 18 years of age).

Eligibility also depends on the ability to safely undergo and maintain the required delivery system, a percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) tube. Therefore, conditions that prohibit the PEG-J procedure, such as intestinal obstruction or peritonitis, make Duopa use unsuitable. Use is not generally recommended for patients with a major psychotic disorder. For pregnant or lactating women, there are no adequate and well-controlled studies, and the component levodopa is known to be present in breast milk.

What should I know about interactions with other medicines?

Duopa (carbidopa and levodopa) enteral suspension can interact with a wide range of prescription and over-the-counter medicines, supplements, and certain foods. Inform your healthcare provider of all products you are taking to safely manage these interactions.

Contraindicated Medications

Duopa is contraindicated with nonselective Monoamine Oxidase Inhibitors (MAOIs), such as tranylcypromine or phenelzine. Concurrent use, or use within two weeks of stopping a nonselective MAOI, can lead to a severe hypertensive crisis (dangerously high blood pressure).

Potential Drug Interactions

Close medical monitoring and possible dose adjustments may be needed with the following:

  • Antihypertensives (Blood Pressure Medicines): Combining these with Duopa may increase the risk of orthostatic hypotension (a drop in blood pressure upon standing), which can cause dizziness or fainting.
  • Dopamine D2 Receptor Antagonists: Medications such as certain antipsychotics and metoclopramide may reduce the effectiveness of Duopa by counteracting the action of levodopa.
  • Isoniazid: This anti-tuberculosis medicine may reduce the effectiveness of Duopa.
  • Selective MAO-B Inhibitors: If taken with Duopa, there is an increased risk of orthostatic hypotension. Dose monitoring is required.

Supplement and Food Interactions

  • Iron Salts/Supplements: Iron can bind to levodopa, significantly reducing its absorption and the effectiveness of Duopa. Iron supplements should generally be taken at a different time of day than Duopa.
  • High-Protein Diet: Consuming a diet high in protein may interfere with the absorption of levodopa, reducing its effect. Consult with your healthcare team or a dietitian regarding appropriate timing and distribution of protein intake.

Mechanism of Action

The action of Duopa is based on a dual mechanism: enzyme protection outside the central nervous system (CNS) and chemical signal restoration within the CNS. The medication utilizes a continuous intestinal infusion to ensure stable drug delivery.

The carbidopa component acts as a peripheral enzyme inhibitor, blocking the aromatic L-amino acid decarboxylase (AADC) enzyme in the systemic circulation. This inhibition prevents the premature breakdown of the levodopa component, making a greater amount of intact levodopa available to cross the blood-brain barrier.

Once inside the brain, the levodopa prodrug is converted by central AADC enzymes into the active signaling molecule, dopamine. This restored dopamine binds to and activates postsynaptic dopamine receptors, modulating activity within the neural circuits that regulate movement. The continuous delivery maintains consistent plasma concentrations of levodopa, which reduces the variability in central receptor stimulation resulting from fluctuating drug levels.

Dosage and Administration Information

How to use Duopa: Official Administration Guidelines

Duopa is a carbidopa and levodopa combination product administered exclusively through the Enteral Route as an intestinal infusion. This long-term administration method requires the surgical placement of a Percutaneous Endoscopic Gastrostomy-Jejunostomy (PEG-J) tube directly into the small intestine, though a temporary Naso-jejunal (NJ) tube may be used for initial testing. Administration is carried out using a specialized portable infusion pump.


Dosing Schedule and Regimen Structure

The total daily dose is highly individualized and is determined through a process of titration based on clinical response. The prescribed regimen is officially composed of three components:

  • Morning Dose: A single, initial bolus delivered over 10 to 30 minutes to initiate the daily cycle.
  • Continuous Dose: The maintenance portion that is infused constantly throughout the day.
  • Extra Doses: Small, pre-set boluses that may be administered intermittently as needed.

The maximum levodopa equivalent administered in a single day is 2000 mg.


Frequency and Administration Conditions

The infusion is scheduled for a 16-hour period during the patient’s waking hours, after which the pump must be disconnected. At night, patients are instructed to take a dose of oral immediate-release carbidopa-levodopa tablets.

Prior to connecting the pump, the cassette containing the suspension must be removed from refrigeration and allowed to reach room temperature for at least 20 minutes. Each cassette is intended for single-use only and must not be used for longer than the 16-hour infusion period. The therapeutic effect may be impacted by concurrent intake of high-protein foods.

Recent Clinical Evidence

Research evidence / Overview of studies for Duopa

Evidence for Use in Advanced Parkinson's Disease and Motor Fluctuations

Duopa (Levodopa-Carbidopa Intestinal Gel, LCIG) was studied for how its continuous administration is evaluated in research exploring how symptoms change over time in individuals with advanced Parkinson's disease (PD) experiencing significant daily motor fluctuations, such as alternating periods of good movement ("On" time) and poor movement ("Off" time), or troublesome involuntary movements (dyskinesia). Research was evaluated in settings involving fluctuating or unstable symptoms that were not adequately managed by optimized oral anti-Parkinsonian medications.

The research included short-term randomized controlled trials (RCTs) using a double-blind design. These pivotal studies were complemented by long-term, non-blinded open-label extension studies to track participant experience over an extended period. The primary focus of these trials was on outcomes related to systemic or functional imbalance, particularly in understanding how symptoms evolve in the observed populations across different forms of treatment.

Outcomes Measured in Core Clinical Trials

The main outcomes researchers monitored in these controlled trials were the duration of daily "Off" time and the duration of "On" time without troublesome dyskinesia. Findings from the short-term RCTs described patterns where researchers reported differences in these primary motor fluctuation outcomes in comparison to the oral therapy. This research also examined outcomes reflecting daily functioning or activity level, using specialized scales which assess activities of daily living (ADL). The evidence contributes to understanding symptom patterns and provides insight into short-term changes during the study periods.


What the Research Evidence Currently Classifies as Uncertain

While research provides insight into short-term changes, several limitations and uncertainties exist in the broader evidence landscape. One key finding is that the sample sizes were modest in the initial pivotal controlled trials, and the evidence quality varies across studies, particularly between the short-term controlled trials and the long-term open-label extensions.

The evidence for long-term outcomes is limited because the follow-up data is predominantly non-blinded and observational. Additionally, comparative evidence is lacking regarding the direct comparison with other forms of device-assisted therapies for PD. Finally, research exploring the outcomes related to non-motor symptoms of Parkinson's disease was associated with findings that were mixed or data are still emerging, indicating that data for certain outcomes remain insufficient in this area.

Key Studies & References

  1. Efficacy and safety of levodopa-carbidopa intestinal gel in patients with advanced Parkinson disease: a systematic review and meta-analysis of randomized controlled trials and observational studies
  2. Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients: Final long-term non-motor, quality of life and safety results from the GLORIA registry (Observational Study)

Frequently Asked Questions (FAQ)

Common questions about Duopa (FAQ)


Q: How quickly can someone expect to see a difference after starting Duopa?

A: The continuous delivery method is intended to maintain stable levels of the medication. Official information indicates that the initial Morning Dose is described as being intended to help initiate the 'On' state before the continuous infusion begins for the rest of the day.


Q: Are there common sleep problems reported with Duopa?

A: Official safety documentation notes insomnia (difficulty sleeping) and somnolence (sleepiness) as commonly reported effects. The label also advises that suddenly falling asleep during daily activities has been reported, sometimes occurring as late as one year after starting the treatment.


Q: What is the typical duration of effect after a dose is delivered?

A: Duopa is not a single-dose pill; it is administered as a continuous infusion over a 16-hour period to maintain stable levels of the drug. The carbidopa component has an elimination half-life of approximately 2 hours, consistent with the drug’s design for sustained, continuous delivery.


Q: Is Duopa a type of extended-release medication?

A: The medication is formally classified as an enteral suspension, which is a liquid gel formulated for continuous infusion. This delivery is classified as an enteral suspension designed for continuous support, which is different from oral extended-release tablets.


Q: What happens if the Duopa pump stops working during the day?

A: In the event of an error or pump stoppage, the device is typically noted to sound an alarm and display an alert. Patient information advises contacting the healthcare provider immediately for guidance, as medication delivery may have been interrupted.


Q: Can the Duopa tube system be disconnected temporarily?

A: The system is intended for continuous infusion throughout the 16-hour dosing period. If the tube needs to be disconnected for a period longer than 2 hours during this time, patient information advises contacting the healthcare provider for guidance regarding potential replacement medication to maintain consistency.


Q: Is it common for people to lose weight while using Duopa?

A: Significant weight decrease is not listed as a common adverse reaction in the main sections of the regulatory label. However, common side effects like nausea and vomiting are documented in the official safety profile.


Q: Do you have to use Duopa 24 hours a day?

A: No. Official prescribing information states that the medicine is administered over a 16-hour infusion period during the patient’s waking hours. Patients are instructed to disconnect the pump for the night and may be prescribed oral carbidopa-levodopa tablets for night-time dosing.


Q: Is Duopa the same as Rytary or Sinemet?

A: Duopa contains the same core active ingredients, carbidopa and levodopa, as products like Sinemet and Rytary. The key difference is the formulation: Duopa is an enteral suspension delivered continuously via a pump and tube directly into the intestine, whereas the other products are oral tablets or capsules.


Q: Is Duopa used in countries outside of the US?

A: Yes. In addition to being available in the United States, official documentation, such as the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC), confirms that Duopa is approved for use in countries within the European Union and other regions.


Q: What research is available on the long-term use of Duopa?

A: The initial effectiveness of the drug was supported by short-term, controlled clinical trials. These studies were complemented by long-term, non-blinded open-label extension studies that tracked participants for an extended period to monitor long-term safety profiles and usage patterns.


Q: Does Duopa affect blood pressure?

A: Yes, official safety information indicates that Duopa can affect blood pressure. Hypertension (high blood pressure) is listed as a common adverse reaction. The label also warns about the risk of orthostatic hypotension (a drop in blood pressure upon standing).

--PIA: Why is Duopa sometimes referred to as 'suspension'?

Q: Why is Duopa sometimes referred to as 'suspension'?

A: The medication is formally referred to as a carbidopa and levodopa enteral suspension because of its form. It is a liquid formulation (a viscous gel) designed for continuous, specialized infusion directly into the small intestine, unlike a solid tablet.


Q: Are there generic versions of Duopa available?

A: According to official regulatory drug listings, there is currently no generic version of the Duopa enteral suspension available in the United States.


Q: How does Duopa treatment start, is there a hospital stay involved?

A: The initial treatment phase involves the placement of the intestinal tube and a titration process to determine the appropriate dose. This process takes place under the direction of a healthcare provider.


Q: Are there restrictions on physical activity while using the Duopa pump?

A: Official guidance describes specific safety precautions for the pump device related to certain activities. Official instructions note that the device is not waterproof and should not be exposed to certain medical equipment, such as MRI or ultrasound.


Q: What if a user accidentally pulls out the tubing for Duopa?

A: If the tubing is accidentally displaced or pulled out, the user should immediately contact their healthcare provider. Official guidance states that the replacement of the tube is an action reserved exclusively for a qualified healthcare professional.


Q: Is Duopa used for movement disorders other than Parkinson's disease?

A: According to official regulatory documents, Duopa is indicated exclusively for the treatment of motor fluctuations in patients with advanced Parkinson’s disease.


Q: Does being elderly change the eligibility for Duopa treatment?

A: Clinical trials did not include a sufficient number of subjects aged 65 and over to definitively conclude that they respond differently from younger subjects. However, official safety data has not consistently observed overall differences in safety or effectiveness between these age groups.


Q: Is it normal to feel dizzy when first starting Duopa?

A: Dizziness is listed as a common side effect of Duopa. Official product information advises monitoring for orthostatic hypotension (a drop in blood pressure when standing) especially during the initial phase of treatment or when the dose is being adjusted.


Q: Is Duopa described as a cure for Parkinson's disease?

A: No. Official documentation classifies Duopa as an anti-Parkinson's agent and a dopamine replacement therapy used to manage the symptoms of the condition.

How should Duopa be stored and disposed of?

Storage and Disposal of Duopa (carbidopa and levodopa) Enteral Suspension

Duopa cassettes must be stored in the refrigerator at a temperature between 2 C and 8 C (36 F to 46 F). It is essential to not freeze the product and to keep it in the original carton protected from light until ready for use. The medication must be kept out of the reach of children.

Before administration, remove the cassette from the refrigerator about 20 minutes prior to use to allow it to reach room temperature. The product is for single-use only and must not be used for more than 16 hours. Any remaining unused product and the cassette itself must be discarded at the end of the 16-hour infusion period, following local regulations for medicinal waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Duopa found in:

A-Z Index: